Agomab director granted 56K stock options

Director Naimish Patel received a stock option grant for 56,328 AgomAb Therapeutics common shares with a $13.94 exercise price and long-term vesting.

Rhea-AI Filing Summary

AgomAb Therapeutics NV (AGMB) reported that director Naimish Patel received a grant of stock options on September 11, 2026. The award covers 56,328 options to purchase common shares at an exercise price of $13.94 per share, expiring on January 15, 2036.

Each option relates to one common share, which may be represented by an American Depositary Share. According to the vesting schedule, 33% of the shares underlying this option vest on September 11, 2027, with the remaining shares vesting in 24 equal monthly installments thereafter, subject to Mr. Patel’s continued service. The exercise price is shown in U.S. dollars based on a $1.1616 per EUR 1.00 exchange rate as of September 10, 2026, and no Rule 10b5-1 trading plan is reported for this grant.

Insider Trade Summary

Grant/Award: 56,328 shares

Grant/Award 1 txn

Insider Patel Naimish

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2, F3	56,328	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 56,328 contracts (Direct)

Footnotes (3)

1. F1. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
2. F2. The exercise price is reported in U.S. dollars and reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026.
3. F3. 33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Stock options granted: 56,328 options Exercise price: $13.94 per share Underlying common shares: 56,328 shares +4 more

7 metrics

Stock options granted 56,328 options Grant to director Naimish Patel on September 11, 2026

Exercise price $13.94 per share Exercise price for Patel’s stock option grant

Underlying common shares 56,328 shares Shares underlying the stock option grant

Vesting tranche 33% Initial portion vesting on September 11, 2027

Vesting period for remainder 24 months Remaining shares vest in 24 equal monthly installments

Option expiration date January 15, 2036 Expiration of Patel’s stock options

FX rate used for exercise price $1.1616 per EUR 1.00 Exchange rate as of September 10, 2026 used to report exercise price in USD

Key Terms

American Depositary Shares, exercise price, vesting, exchange rate

4 terms

American Depositary Shares financial

"The common shares may be represented by American Depositary Shares, each of which"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

exercise price financial

"The exercise price is reported in U.S. dollars and reflects the conversion"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"33% of the shares underlying this option shall vest on September 11, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exchange rate financial

"reflects the conversion from EUR to USD at an exchange rate of $1.1616"

Exchange rate is the price of one currency expressed in another—for example, how many euros you receive for one US dollar. It matters to investors because changes in that price alter the reported profits, costs and value of assets for companies and portfolios that operate or hold money across borders; think of it like switching measurement units, where the same item can look bigger or smaller depending on the unit used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AGMB report for director Naimish Patel?

AGMB reported that director Naimish Patel received a grant of 56,328 stock options on September 11, 2026, to purchase common shares at an exercise price of $13.94 per share, expiring on January 15, 2036.

What is the vesting schedule for Naimish Patel’s AGMB stock options?

33% of the shares underlying Mr. Patel’s stock option vest on September 11, 2027. The remaining shares vest in 24 equal monthly installments after that date, conditioned on his continued service on each vesting date.

How many AGMB shares underlie the stock options granted to Naimish Patel?

The stock option grant to Naimish Patel covers 56,328 underlying common shares. Each option is exercisable for one common share, which may be represented by an American Depositary Share.

What is the exercise price and currency basis of Naimish Patel’s AGMB options?

The options have an exercise price of $13.94 per share. This price is reported in U.S. dollars and reflects conversion from euros using an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026.

Were Naimish Patel’s AGMB option grants made under a Rule 10b5-1 plan?

No. The filing indicates no Rule 10b5-1 plan is reported for this stock option grant to director Naimish Patel.

When do Naimish Patel’s AGMB stock options expire?

The stock options granted to Naimish Patel expire on January 15, 2036, if not exercised earlier and subject to their vesting terms and his continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:07 PM Accepted by SEC EDGAR 09/15/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Naimish

(Last) (First) (Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN 2600

(City) (State) (Zip)

BELGIUM

(Country)

2. Issuer Name and Ticker or Trading Symbol
AgomAb Therapeutics NV [ AGMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.94(1)	09/11/2026		A		56,328		(2)	01/15/2036	Common shares(3)	56,328	$0.00	56,328	D

Explanation of Responses:

1. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

2. The exercise price is reported in U.S. dollars and reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026.

3. 33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Ellen Lefever, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)